Cargando…

Successful Treatment of Atopic Dermatitis with a Predominant Nipple Involvement by Abrocitinib During COVID-19 Pandemic: A Case Report

BACKGROUND: There is limited literature on AD with a predominant involvement of nipple among the adult male group. SARS-CoV-2 infection might have been an exacerbating factor of AD by initiating the “cytokine storm”. Conventional treatment suffers from a dilemma of poor efficacy and a high recurrenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Teng, Yan, Tang, Hui, Yu, Yong, Fan, Yibin, Tao, Xiaohua, Xu, Danfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404034/
https://www.ncbi.nlm.nih.gov/pubmed/37547036
http://dx.doi.org/10.2147/JAA.S422836
_version_ 1785085206427860992
author Teng, Yan
Tang, Hui
Yu, Yong
Fan, Yibin
Tao, Xiaohua
Xu, Danfeng
author_facet Teng, Yan
Tang, Hui
Yu, Yong
Fan, Yibin
Tao, Xiaohua
Xu, Danfeng
author_sort Teng, Yan
collection PubMed
description BACKGROUND: There is limited literature on AD with a predominant involvement of nipple among the adult male group. SARS-CoV-2 infection might have been an exacerbating factor of AD by initiating the “cytokine storm”. Conventional treatment suffers from a dilemma of poor efficacy and a high recurrence. The JAK inhibitors have been clinically applied to treat the AD with a good outcome. PATIENTS AND METHODS: We present a case of a 28-year-old male AD patient with a predominant nipple involvement successfully treated with JAK inhibitor abrocitinib, with no adverse affects. RESULTS: The case shows a good clinical efficacy of JAK inhibitor abrocitinib in the treatment of AD with a predominant nipple involvement during the COVID-19 pandemic with a rapid and long-term symptomatic relief. CONCLUSION: JAK inhibitor abrocitinib might become a promising agent for the treatment with AD with a predominant uncommon region like nipple that might be resistant to conventional therapies during the COVID-19 pandemic.
format Online
Article
Text
id pubmed-10404034
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-104040342023-08-06 Successful Treatment of Atopic Dermatitis with a Predominant Nipple Involvement by Abrocitinib During COVID-19 Pandemic: A Case Report Teng, Yan Tang, Hui Yu, Yong Fan, Yibin Tao, Xiaohua Xu, Danfeng J Asthma Allergy Case Report BACKGROUND: There is limited literature on AD with a predominant involvement of nipple among the adult male group. SARS-CoV-2 infection might have been an exacerbating factor of AD by initiating the “cytokine storm”. Conventional treatment suffers from a dilemma of poor efficacy and a high recurrence. The JAK inhibitors have been clinically applied to treat the AD with a good outcome. PATIENTS AND METHODS: We present a case of a 28-year-old male AD patient with a predominant nipple involvement successfully treated with JAK inhibitor abrocitinib, with no adverse affects. RESULTS: The case shows a good clinical efficacy of JAK inhibitor abrocitinib in the treatment of AD with a predominant nipple involvement during the COVID-19 pandemic with a rapid and long-term symptomatic relief. CONCLUSION: JAK inhibitor abrocitinib might become a promising agent for the treatment with AD with a predominant uncommon region like nipple that might be resistant to conventional therapies during the COVID-19 pandemic. Dove 2023-08-01 /pmc/articles/PMC10404034/ /pubmed/37547036 http://dx.doi.org/10.2147/JAA.S422836 Text en © 2023 Teng et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Teng, Yan
Tang, Hui
Yu, Yong
Fan, Yibin
Tao, Xiaohua
Xu, Danfeng
Successful Treatment of Atopic Dermatitis with a Predominant Nipple Involvement by Abrocitinib During COVID-19 Pandemic: A Case Report
title Successful Treatment of Atopic Dermatitis with a Predominant Nipple Involvement by Abrocitinib During COVID-19 Pandemic: A Case Report
title_full Successful Treatment of Atopic Dermatitis with a Predominant Nipple Involvement by Abrocitinib During COVID-19 Pandemic: A Case Report
title_fullStr Successful Treatment of Atopic Dermatitis with a Predominant Nipple Involvement by Abrocitinib During COVID-19 Pandemic: A Case Report
title_full_unstemmed Successful Treatment of Atopic Dermatitis with a Predominant Nipple Involvement by Abrocitinib During COVID-19 Pandemic: A Case Report
title_short Successful Treatment of Atopic Dermatitis with a Predominant Nipple Involvement by Abrocitinib During COVID-19 Pandemic: A Case Report
title_sort successful treatment of atopic dermatitis with a predominant nipple involvement by abrocitinib during covid-19 pandemic: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404034/
https://www.ncbi.nlm.nih.gov/pubmed/37547036
http://dx.doi.org/10.2147/JAA.S422836
work_keys_str_mv AT tengyan successfultreatmentofatopicdermatitiswithapredominantnippleinvolvementbyabrocitinibduringcovid19pandemicacasereport
AT tanghui successfultreatmentofatopicdermatitiswithapredominantnippleinvolvementbyabrocitinibduringcovid19pandemicacasereport
AT yuyong successfultreatmentofatopicdermatitiswithapredominantnippleinvolvementbyabrocitinibduringcovid19pandemicacasereport
AT fanyibin successfultreatmentofatopicdermatitiswithapredominantnippleinvolvementbyabrocitinibduringcovid19pandemicacasereport
AT taoxiaohua successfultreatmentofatopicdermatitiswithapredominantnippleinvolvementbyabrocitinibduringcovid19pandemicacasereport
AT xudanfeng successfultreatmentofatopicdermatitiswithapredominantnippleinvolvementbyabrocitinibduringcovid19pandemicacasereport